CRISPR Therapeutics AG
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Revenue | $41.0M | $5.2M | $247.0K |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $69.8M | $42.2M | $12.6M |
| SG&A Expense | $35.8M | $31.1M | $13.4M |
| Operating Income | $-64.6M | $-68.1M | $-25.7M |
| Operating Margin | -157.7% | -1,319.3% | -10,416.6% |
| Interest Expense | — | — | — |
| Pretax Income | $-66.6M | $-22.7M | $-25.8M |
| Income Tax Expense | $1.7M | $484.0K | $7.0K |
| Net Income | $-68.4M | $-23.2M | $-25.5M |
| Net Margin | -166.7% | -448.8% | -10,325.1% |
| EPS (Basic) | $-1.71 | $-1.89 | $-5.06 |
| EPS (Diluted) | $-1.71 | $-1.89 | $-5.06 |
| Shares Outstanding (Basic) | 40.1M | 39.7M | 5.5M |
| Shares Outstanding (Diluted) | 40.1M | 39.7M | 5.5M |
| Dividends Per Share | — | — | — |